AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through Ampligen

Additional commentary published discussing the potential of Ampligen and two other drugs